-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Several second-line treatment options are available to rheumatologists and patients for patients with rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) or who have contraindications
Methods: In this observational cohort study, patients initiated on tumor necrosis factor inhibitors (TNFi), interleukin-6 inhibitors (IL-6i), abatacept (ABA), or JAKi were included
RESULTS: A total of 31,846 courses were included in the study: 17,522 TNFi, 2,775 ABA, 3,863 IL-6i, and 7,686 JAKi
CONCLUSIONS: JAKi- and IL-6i-adjusted overall discontinuation rates and 1-year remission rates were similar to those observed with TNFi
Source: Lauper K, Iudici M, Mongin D, et al.